SCHEMBL1707313

SCHEMBL1707313

CON(C)C(=O)Cc1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.46
RIPK1 Q13546 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CCR5 P51681 1/20 0.45
CLK1 P49759 1/20 0.44
CLK2 P49760 1/20 0.44
DYRK1A Q13627 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
MAOB P27338 3/20 0.43
PTPRB P23467 1/20 0.42
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
NR4A2 P43354 1/20 0.41
IDO1 P14902 1/20 0.41
AGXT P21549 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16071011 0.85 TAAR1 (0.51) TAAR1RIPK1MEN1KMT2ACLK1
SCHEMBL4084155 0.84 AGXT (0.48) TRPM8HDAC4HDAC6AGXTMRGPRX4
SCHEMBL1058423 0.84 CTBP2 (0.50) MEN1KMT2AMAOBIDO1
SCHEMBL20551648 0.83 HDAC4 (0.42) TRPM8MEN1KMT2ACLK1CLK2
SCHEMBL1515860 0.83 LMNA (0.43) KMT2AHDAC4HDAC6
SCHEMBL6376386 0.81 ALOX5 (0.43) HDAC4HDAC6
SCHEMBL22607856 0.81 IDO1 (0.41) HDAC4HDAC6IDO1
SCHEMBL904249 0.81 SIGMAR1 (0.57) MEN1KMT2ACCR5
SCHEMBL6584298 0.81 ALOX5 (0.56) TAAR1RIPK1MEN1KMT2ACCR5
SCHEMBL1515805 0.81 TAAR1 (0.46) TAAR1RIPK1MAOBHCAR2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981877-B1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLAS PHARMA INC (JP) 2012-04-18 EP disclosed
US-7750155-B2 Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase ASTELLAS PHARMA INC. (JP) 2010-07-06 US disclosed
US-20090054465-A1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLA PHARMA INC. (JP) 2009-02-26 US disclosed
EP-1981877-A1 N-HYDROXYACRYLAMIDE COMPOUNDS Astellas Pharma Inc. (JP) 2008-10-22 EP disclosed
WO-2007091703-A1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054465-A1 N-HYDROXYACRYLAMIDE COMPOUNDS HDAC1, HDAC6, HDAC5 TAAR1 3104/4885RIPK1 4361/4885TRPM8 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.